Canada Markets closed

EyeGate Pharmaceuticals, Inc. (EYEG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9500-0.0300 (-1.52%)
At close: 03:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.9800
Open1.9851
Bid0.0000 x 1800
Ask0.0000 x 800
Day's Range1.9200 - 1.9950
52 Week Range1.2827 - 8.1800
Volume321,303
Avg. Volume1,574,455
Market Cap13.841M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy

    SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Company’s aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degen

  • GlobeNewswire

    EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

    EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline Eric J. Daniels, MD, MBA EyeGate Pharma's new Chief Development Officer WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon

  • GlobeNewswire

    EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate’s President and Chief Executive Officer, Brian M. Strem, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held S